Notable

Notable is a clinical-stage platform therapeutic company founded in 2014, with a mission to transform the way cancer is treated. The company's proprietary Predictive Precision Medicines Platform replicates ex vivo the clinical response of patients to cancer treatments with high fidelity, through its optimized integration of biological assay conditions, dynamic signal analysis, and AI-driven in-silico translation into predictive algorithms. Notable aims to be the leader in predictive precision medicine and revolutionize the way in which patients seek and receive treatment, patient population by patient population, and cancer by cancer. The company's last investment was a Series B investment on 01 July 2022, with participation from notable investors including Duro Ventures, Bioverge Ventures, and Milad Alucozai. Notable's focus on developing a new class of precision medicines, specifically predictive precision medicines, positions them at the forefront of innovation in the Biotechnology and Health Care industries. The company's approach, which includes a targeted, triple de-risked in-licensing strategy and a fast-track clinical development approach, holds the promise of delivering significant medical impact and commercial value faster and more effectively than traditional drug development methods.